1. Home
  2. PRT vs COCP Comparison

PRT vs COCP Comparison

Compare PRT & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

SELL

Current Price

$1.42

Market Cap

18.0M

Sector

Energy

ML Signal

SELL

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

SELL

Current Price

$0.96

Market Cap

19.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PRT
COCP
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0M
19.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
PRT
COCP
Price
$1.42
$0.96
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $8.00
AVG Volume (30 Days)
★ 49.8K
30.2K
Earning Date
11-27-2026
11-15-2026
Dividend Yield
★ 14.03%
N/A
EPS Growth
N/A
★ 54.65
EPS
★ N/A
N/A
Revenue
N/A
★ $12,712,091.00
Revenue This Year
$654.36
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$0.76
52 Week High
$3.95
$2.03

Technical Indicators

Market Signals
Indicator
PRT
COCP
Relative Strength Index (RSI) 35.81 45.81
Support Level $1.20 $0.95
Resistance Level $2.32 $1.12
Average True Range (ATR) 0.07 0.06
MACD 0.02 0.00
Stochastic Oscillator 66.67 26.11

Price Performance

Historical Comparison
PRT
COCP

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: